Schulhoff & Co. Inc. Acquires New Stake in CytomX Therapeutics, Inc. $CTMX

Schulhoff & Co. Inc. acquired a new stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 374,850 shares of the biotechnology company’s stock, valued at approximately $1,597,000.

A number of other hedge funds also recently bought and sold shares of CTMX. Invesco Ltd. purchased a new stake in CytomX Therapeutics during the second quarter valued at $32,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in CytomX Therapeutics in the fourth quarter worth about $35,000. Goldman Sachs Group Inc. purchased a new stake in CytomX Therapeutics in the first quarter worth about $39,000. Truist Financial Corp purchased a new stake in CytomX Therapeutics in the third quarter worth about $40,000. Finally, May Hill Capital LLC purchased a new stake in CytomX Therapeutics in the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Wall Street Analysts Forecast Growth

CTMX has been the subject of a number of analyst reports. Guggenheim upped their price target on CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Barclays upped their price target on CytomX Therapeutics from $10.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Oppenheimer restated an “outperform” rating and issued a $12.00 price target on shares of CytomX Therapeutics in a research report on Monday, March 16th. Weiss Ratings cut CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, March 19th. Finally, Piper Sandler upped their price target on CytomX Therapeutics from $10.00 to $12.00 and gave the stock an “overweight” rating in a research report on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $12.10.

CytomX Therapeutics Price Performance

NASDAQ CTMX opened at $3.00 on Monday. The firm has a market cap of $510.56 million, a price-to-earnings ratio of -7.32 and a beta of 2.08. The business has a 50-day moving average price of $4.09 and a 200-day moving average price of $4.52. CytomX Therapeutics, Inc. has a twelve month low of $1.72 and a twelve month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The firm had revenue of $10.26 million during the quarter, compared to analyst estimates of $4.68 million. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%. Research analysts expect that CytomX Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Marcia Belvin sold 31,492 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $202,178.64. Following the completion of the transaction, the senior vice president owned 300,760 shares of the company’s stock, valued at $1,930,879.20. This represents a 9.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Christopher Ogden sold 19,323 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the completion of the transaction, the chief financial officer directly owned 296,948 shares of the company’s stock, valued at approximately $1,906,406.16. This trade represents a 6.11% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 191,063 shares of company stock worth $1,226,624. 6.60% of the stock is currently owned by insiders.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.